Company announces change to senior management team
LAVAL, QC, July 17 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) announced today the closing of the acquisition of Innodia Inc. that it had previously announced on July 16, 2008.
As a result of this acquisition, BELLUS Health is also announcing a change at the management level in the field of research. Nigel Levens, Ph.D., Chief Scientific Officer of Innodia Inc. will take on the position of Vice President, Research at BELLUS Health while Daniel Delorme, Ph.D., BELLUS Health's current Vice President, Research, will be leaving the Company to pursue other interests.
"I am very pleased to welcome Dr. Levens to the Company," said Dr. Francesco Bellini, Chairman, President and CEO of BELLUS Health. "The expertise he demonstrated in drug discovery for metabolic diseases at Innodia, will serve us very well at BELLUS Health. I also want to thank Dr. Delorme for his valuable contribution to the Company during his tenure with us and wish him great success in his future endeavours."
Dr. Levens brings to the position 27 years of teaching and research in
the field of metabolic and cardiovascular diseases in both Europe and North
America. Prior to joining Innodia in 2006, he worked as Head of Biology for
Biovitrum AB of Sweden, which specializes in metabolic diseases such as
Type II diabetes, obesity, and metabolic syndrome. From 1998-2003, he
served as Head of the Division of Metabolic Diseases for the Servier
Research Group in France and prior to that as Head of Obesity Pharmacology
for Novartis Pharma in Basel, Switzerland. Educated in both the United
Kingdom and the United States, Dr. Levens holds a B.Sc. (Hons.) in
Physiology and Biochemistry, and a Ph.D. in Physiology from the University
of Southampton in the United Kingdom and conducted a postdoctoral
|SOURCE BELLUS HEALTH INC.|
Copyright©2008 PR Newswire.
All rights reserved